Deodhar A, Helliwell PS, Boehncke WH, et al. - A double-blind, randomised, placebo-controlled phase 3 trial was designed to evaluate the utility and safety of guselkumab in individuals with active psoriatic arthritis who were biologic-naive or had previously received tumor necrosis factor-α inhibitor treatment. This trial was performed at 86 sites in 13 countries across Asia, Australasia, Europe, and North America and enrolled adults with active psoriatic arthritis (at least three swollen and three tender joints; and C-reactive protein ≥ 0·3 mg/dL) despite standard therapies. In this study, 624 individuals were screened, of whom 381 were randomized and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126). For individuals with active psoriatic arthritis, guselkumab indicated a favourable benefit–risk profile and might be an effective treatment option.